<prompt> Selegiline acts by:MAO-A inhibitionMAO-B inhibitionCOMT inhibitionDopamine receptor stimulator  <response>: Ref: Katzung 14th ed. pg. 499 After release of DA in synaptic cleft, it is metabolized either by MAO-b or by COMT catechol-ortho methyl transferase In order to prevent this metabolism following drugs can be given, which will enhance DA availability: MAO-b inhibitor: Selegiline, Rasagiline, safinamide COMT inhibitor: Entacapone, TolcaponeDrugs stimulating DA receptor: Ergot Derivative: Bromocriptine, Cabergoline Non-Ergot: Pramipexole, Ropinirole, Rotigotine available as transdermal patch 